Cargando…

Molecular signatures of multiple myeloma progression through single cell RNA-Seq

We used single cell RNA-Seq to examine molecular heterogeneity in multiple myeloma (MM) in 597 CD138 positive cells from bone marrow aspirates of 15 patients at different stages of disease progression. 790 genes were selected by coefficient of variation (CV) method and organized cells into four grou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Jin Sung, Li, Ying, Mitra, Amit Kumar, Bi, Lintao, Abyzov, Alexej, van Wijnen, Andre J., Baughn, Linda B., Van Ness, Brian, Rajkumar, Vincent, Kumar, Shaji, Jen, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318319/ https://www.ncbi.nlm.nih.gov/pubmed/30607001 http://dx.doi.org/10.1038/s41408-018-0160-x

Ejemplares similares

In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma
por: Mitra, Amit Kumar, et al.
Publicado: (2020)

secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics
por: Kumar, Harish, et al.
Publicado: (2022)

Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells
por: Kumar, Harish, et al.
Publicado: (2022)

Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2018)

Multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2020)

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
por: Mitra, A K, et al.
Publicado: (2017)

Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
por: Ramakrishnan, Vijay, et al.
Publicado: (2016)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma
por: Baughn, Linda B., et al.
Publicado: (2023)

Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
por: Ramakrishnan, Vijay, et al.
Publicado: (2014)

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
por: Sharma, Neeraj, et al.
Publicado: (2021)

Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma
por: Fall, Deanna J., et al.
Publicado: (2014)

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
por: Ramakrishnan, Vijay, et al.
Publicado: (2012)

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies
por: Ravi, Praful, et al.
Publicado: (2018)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Bortezomib Resistance Can Be Reversed by Induced Expression of Plasma Cell Maturation Markers in a Mouse In Vitro Model of Multiple Myeloma
por: Stessman, Holly A. F., et al.
Publicado: (2013)

P975: THREE-DIMENSIONAL TELOMERE PROFILING PREDICTS RISK OF RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Kumar, Shaji, et al.
Publicado: (2023)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
por: Greenberg, Alexandra J., et al.
Publicado: (2013)

Conditional survival in multiple myeloma and impact of prognostic factors over time
por: Abdallah, Nadine H., et al.
Publicado: (2023)

AGE: defining breakpoints of genomic structural variants at single-nucleotide resolution, through optimal alignments with gap excision
por: Abyzov, Alexej, et al.
Publicado: (2011)

Elevated variant density around SV breakpoints in germline lineage lends support to error-prone replication hypothesis
por: Dhokarh, Dhananjay, et al.
Publicado: (2016)

Chromatin organization modulates the origin of heritable structural variations in human genome
por: Roychowdhury, Tanmoy, et al.
Publicado: (2019)

LongAGE: defining breakpoints of genomic structural variants through optimal and memory efficient alignments of long reads
por: Tran, Quang, et al.
Publicado: (2020)

Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma
por: Smadbeck, James, et al.
Publicado: (2019)

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
por: Ramakrishnan, Vijay G., et al.
Publicado: (2019)

Extramedullary disease in multiple myeloma
por: Bansal, Radhika, et al.
Publicado: (2021)

RWD-derived response in multiple myeloma
por: Xu, Tao, et al.
Publicado: (2023)

A comprehensive analysis of non-sequential alignments between all protein structures
por: Abyzov, Alexej, et al.
Publicado: (2007)

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
por: Abdallah, Nadine, et al.
Publicado: (2020)

Post-Transplant Maintenance Treatment Options in Multiple Myeloma
por: Karam, Dhauna, et al.
Publicado: (2021)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)

Immune-based therapies in the management of multiple myeloma
por: Zanwar, Saurabh, et al.
Publicado: (2020)

High Levels of Peripheral Blood Circulating Plasma Cells as a Specific Risk Factor for Progression of Smoldering Multiple Myeloma
por: Bianchi, Giada, et al.
Publicado: (2012)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
por: Murray, David L., et al.
Publicado: (2021)

A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors
por: Mitra, Amit Kumar, et al.
Publicado: (2016)

Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
por: Larsen, Jeremy T., et al.
Publicado: (2015)

Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms
por: Gagnon, Marie-France, et al.
Publicado: (2022)

AlleleSeq: analysis of allele-specific expression and binding in a network framework
por: Rozowsky, Joel, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hv6eho899tfa4e0admn2pdqup3